NR3C1 and neoplasm: In the initial phase 1 study of another GR antagonist, relacorilant (Corcept Therapeutics), in combination with nab-paclitaxel, 3/57 (5%) response-evaluable patients with various tumor types achieved an objective response after progressing on prior taxane for metastatic disease (18).